Impacto económico del uso de patiromer en enfermedad renal crónica o insuficiencia cardíaca para el tratamiento de la hiperpotasemia crónica en España

Sequera, Patricia de; Bover, Ramón; Ivanova-Markova, Yoana; Ivanova, Alexandraa; González-Domínguez, Almudenaa; Valls, Marta; Campos, Verónica.
Nefrología (Madrid) ; 43(6): 721-730, nov.- dec. 2023. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-228010

Documentos relacionados

  1. Fund Black scientists.
  2. Attitude changes in prescribing intravenous iron supplementation in different settings at a hospital consortium in Italy.
  3. Principal-agent theory-based cost and reimbursement structures of isavuconazole treatment in German hospitals.
  4. Development and Impact of an Institutional Enhanced Recovery Program on Opioid Use, Length of Stay, and Hospital Costs Within an Academic Medical Center: A Cohort Analysis of 7774 Patients.
  5. An Updated Economic Assessment of Moxidectin Treatment Strategies for Onchocerciasis Elimination.
  6. Interventional Imaging Systems in Radiology, Cardiology, and Urology: Energy Consumption, Carbon Emissions, and Electricity Costs.
  7. Global access to affordable direct oral anticoagulants.
  8. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.
  9. From scientific discovery to cures: bright stars within a galaxy.
  10. Hospital Prices for Physician-Administered Drugs for Patients with Private Insurance.